Adenoviral-Mediated Expression of a Kinase-Dead Mutant of Akt Induces Apoptosis Selectively in Tumor Cells and Suppresses Tumor Growth in Mice

Cancer Research

Volumn 63, Issue 20, 2003, Pages 6697-6706

  Jetzt, Amanda ^a   Howe, John A ^a   Horn, Mark T ^a   Maxwell, Eugene ^a   Yin, Zhizhang ^b   Johnson, Duane ^a   Kumar, C Chandra ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Canji Inc ^*

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE;

ADVANCED CANCER; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL SURVIVAL; GENE INDUCTION; GENE MUTATION; GROWTH INHIBITION; MOUSE; MULTIPLE ADVANCED CANCER SUPPRESSOR GENE; MULTIPLE CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR UPREGULATION; TUMOR CELL CULTURE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; VIRUS EXPRESSION;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; GENE THERAPY; HUMANS; MELANOMA; MICE; MICE, INBRED BALB C; MUTATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0142188728     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Staal, S. P. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl. Acad. Sci. USA, 84: 5034-5037, 1987.
2. Vivanco, I., and Sawyers, C. L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer, 2: 489-501, 2002.
3. Brazil, D. P., and Hemmings, B. A. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem. Sci., 26: 657-664, 2001.
4. Lawlor, M. A., and Alessi, D. R. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J. Cell Sci., 114: 2903-2910, 2001.
5. Datta, S. R., Brunet, A., and Greenberg, M. E. Cellular survival: a play in three Akts. Genes Dev., 13: 2905-2927, 1999.
6. Testa, J. R., and Bellacosa, A. AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. USA, 98: 10983-10985, 2001.
7. Testa, J. R., and Bellacosa, A. Membrane translocation and activation of the Akt kinase in growth factor-stimulated hematopoietic cells. Leuk. Res., 21: 1027-1031, 1997.
8. Alessi, D. R., and Cohen, P. Mechanism of activation and function of protein kinase B. Curr. Opin. Genet. Dev., 8: 55-62, 1998.
9. Maehama, T., and Dixon, J. E. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol., 9: 125-128, 1999.
10. Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., Frye, C., Hu, R., Swedlund, B., Teng, D. H., and Tavtigian, S. V. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet., 15: 356-362, 1997.
11. Li, J., Simpson, L., Takahashi, M., Miliaresis, C., Myers, M. P., Tonks, N., and Parsons, R. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res., 58: 5667-5672, 1998.
12. Simpson, L., and Parsons, R. PTEN: life as a tumor suppressor. Exp. Cell Res., 264: 29-41, 2001.
13. Myers, M. P., Pass, I., Batty, I. H., Van der Kaay, J., Stolarov, J. P., Hemmings, B. A., Wigler, M. H., Downes, C. P., and Tonks, N. K. The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc. Natl. Acad. Sci. USA, 95: 13513-13518, 1998.
14. Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg, M. E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 91: 231-241, 1997.
15. Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., and Reed, J. C. Regulation of cell death protease caspase-9 by phosphorylation. Science (Washington DC), 282: 1318-1321, 1998.
16. Kops, G. J., and Burgering, B. M. Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling. J. Mol. Med., 77: 656-665, 1999.
17. Romashkova, J. A., and Makarov, S. S. NF-κB is a target of AKT in anti-apoptotic PDGF signalling. Nature (Lond.), 401: 86-90, 1999.
18. Mayo, L. D., and Donner, D. B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. USA, 98: 11598-11603, 2001.
19. Dijkers, P. F., Medema, R. H., Lammers, J. W., Koenderman, L., and Coffer, P. J. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr. Biol., 10: 1201-1204, 2000.
20. Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., and Greenberg, M. E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell, 96: 857-868, 1999.
21. Samatar, A. A., Wang, L., Mirza, A., Koseoglu, S., Liu, S., and Kumar, C. C. Transforming growth factor-β2 is a transcriptional target for Akt/PKB via forkhead transcription factor. J. Biol. Chem., 14: 14, 2002.
22. cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell Biol., 3: 245-252, 2001.
23. Kip1. J. Biol. Chem., 275: 21960-21968, 2000.
24. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature (Lond.), 378: 785-789, 1995.
25. Diehl, J. A., Cheng, M., Roussel, M. F., and Sherr, C. J. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev., 12: 3499-3511, 1998.
26. Ali, I. U., Schriml, L. M., and Dean, M. Mutational spectra of PTEN/ MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J. Natl. Cancer Inst., 91: 1922-1932, 1999.
27. Brognard, J., Clark, A. S., Ni, Y., and Dennis, P. A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res., 61: 3986-3997, 2001.
28. Cuello, M., Ettenberg, S. A., Clark, A. S., Keane, M. M., Posner, R. H., Nau, M. M., Dennis, P. A., and Lipkowitz, S. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res., 61: 4892-4900, 2001.
29. Dudek, H., Datta, S. R., Franke, T. F., Birnbaum, M. J., Yao, R., Cooper, G. M., Segal, R. A., Kaplan, D. R., and Greenberg, M. E. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science (Washington DC), 275: 661-665, 1997.
30. Nielsen, L. L., Gurnani, M., Shi, B., Terracina, G., Johnson, R. C., Carroll, J., Mathis, J. M., and Hajian, G. Derivation and initial characterization of a mouse mammary tumor cell line carrying the polyomavirus middle T antigen: utility in the development of novel cancer therapeutics. Cancer Res., 60: 7066-7074, 2000.
31. Kumar, C. C., Diao, R., Yin, Z., Liu, Y., Samatar, A. A., Madison, V., and Xiao, L. Expression, purification, characterization and homology modeling of active Akt/PKB, a key enzyme involved in cell survival signaling. Biochim. Biophys. Acta, 1526: 257-268, 2001.
32. Wills, K. N., Maneval, D. C., Menzel, P., Harris, M. P., Sutjipto, S., Vaillancourt, M. T., Huang, W. M., Johnson, D. E., Anderson, S. C., Wen, S. F., Bookstein, R., Shepard, H. M., and Gregory, R. J. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum. Gene Ther., 5: 1079-1088, 1994.
33. Cheney, I. W., Johnson, D. E., Vaillancourt, M. T., Avanzini, J., Morimoto, A., Demers, G. W., Wills, K. N., Shabram, P. W., Bolen, J. B., Tavtigian, S. V., and Bookstein, R. Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res., 58: 2331-2334, 1998.
34. Chartier, C., Degryse, E., Gantzer, M., Dieterle, A., Pavirani, A., and Mehtali, M. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J. Virol., 70: 4805-4810, 1996.
35. Shabram, P. W., Giroux, D. D., Goudreau, A. M., Gregory, R. J., Horn, M. T., Huyghe, B. G., Liu, X., Nunnally, M. H., Sugarman, B. J., and Sutjipto, S. Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Hum. Gene Ther., 8: 453-465, 1997.
36. Kitamura, T., Ogawa, W., Sakaue, H., Hino, Y., Kuroda, S., Takata, M., Matsumoto, M., Maeda, T., Konishi, H., Kikkawa, U., and Kasuga, M. Requirement for activation of the serine-threonine kinase Akt (protein kinase B) in insulin stimulation of protein synthesis but not of glucose transport. Mol. Cell. Biol., 18: 3708-3717, 1998.
37. Kotani, K., Ogawa, W., Hino, Y., Kitamura, T., Ueno, H., Sano, W., Sutherland, C., Granner, D. K., and Kasuga, M. Dominant negative forms of Akt (protein kinase B) and atypical protein kinase Cλ do not prevent insulin inhibition of phosphoenolpyruvate carboxykinase gene transcription. J. Biol. Chem., 274: 21305-21312, 1999.
38. Nakae, J., Kitamura, T., Ogawa, W., Kasuga, M., and Accili, D. Insulin regulation of gene expression through the forkhead transcription factor Foxo1 (Fkhr) requires kinases distinct from Akt. Biochemistry, 40: 11768-11776, 2001.
39. Di Cristofano, A., and Pandolfi, P. P. The multiple roles of PTEN in tumor suppression. Cell, 100: 387-390, 2000.
40. Atcncio, I. A., Ramachandra, M., Shabram, P., and Demers, G. W. Calpain inhibitor 1 activates p53-dependent apoptosis in tumor cell lines. Cell Growth Differ., 11: 247-253, 2000.
41. Atencio, I. A., Avanzini, J. B., Johnson, D., Neuteboom, S., Vaillancourt, M. T., Nielsen, L. L., Hajian, G., Sutjipto, S., Sugarman, B. J., Philopena, J., McAllister, D. L., Beltran, J. C., Nodelman, M., Ramachandra, M., and Wills, K. N. Enhanced apoptotic activity of a p53 variant in tumors resistant to wild-type p53 treatment. Mol. Ther., 4: 5-12, 2001.
42. Harris, M. P., Sutjipto, S., Wills, K. N., Hancock, W., Cornell, D., Johnson, D. E., Gregory, R. J., Shepard, H. M., and Maneval, D. C. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther., 3: 121-130, 1996.
43. Clark, A. S., West, K., Streicher, S., and Dennis, P. A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther., 1: 707-717, 2002.
44. Grunwald, V., DeGraffenried, L., Russel, D., Friedrichs, W. E., Ray, R. B., and Hidalgo, M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res., 62: 6141-6145, 2002.
45. Beroud, C., and Soussi, T. p53 gene mutation: software and database. Nucleic Acids Res., 26: 200-204, 1998.
46. Jeffy, B. D., Chirnomas, R. B., Chen, E. J., Gudas, J. M., and Romagnolo, D. F. Activation of the aromatic hydrocarbon receptor pathway is not sufficient for transcriptional repression of BRCA-1: requirements for metabolism of benzo[a] pyrene to 7r, 8t-dihydroxy-9t,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene. Cancer Res., 62: 113-121, 2002.
47. Colletier, P. J., Ashoori, F., Cowen, D., Meyn, R. E., Tofilon, P., Meistrich, M. E., and Pollack, A. Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation. Int. J. Radiat. Oncol. Biol. Phys., 48: 1507-1512, 2000.
48. Murakami, Y., and Sekiya, T. Accumulation of genetic alterations and their significance in each primary human cancer and cell line. Mutat. Res., 400: 421-437, 1998.
49. Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., and Sawyers, C. L. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA, 98: 10314-10319, 2001.
50. Zhou, B. P., Hu, M. C., Miller, S. A., Yu, Z., Xia, W., Lin, S. Y., and Hung, M. C. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NFκB pathway. J. Biol. Chem., 275: 8027-8031, 2000.
51. Liu, X., Shi, Y., Han, E. K., Chen, Z., Rosenberg, S. H., Giranda, V. L., Luo, Y., and Ng, S. C. Downregulation of Akt1 inhibits anchorage-independent cell growth and induces apoptosis in cancer cells. Neoplasia, 3: 278-286, 2001.
52. Haas-Kogan, D., Shalev, N., Wong, M., Mills, G., Yount, G., and Stokoe, D. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr. Biol., 8: 1195-1198, 1998.
53. Khwaja, A., Rodriguez-Viciana, P., Wennstrom, S., Warne, P. H. A., and Downward, J. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J., 16: 2783-2793, 1997.
54. 1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Rcs., 63: 196-206, 2003.
55. Hill, M., and Hemmings, B. Inhibition of protein kinase B/Akt, implications for cancer therapy. Pharmacol. Ther., 93: 243-251, 2002.
56. Dhawan, P., Singh, A. B., Ellis, D. L., and Richmond, A. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-κB and tumor progression. Cancer Res., 62: 7335-7342, 2002.
57. Sekulic, A., Hudson, C. C., Homme, J. L., Yin, P., Otterness, D. M., Karnitz, L. M., and Abraham, R. T. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res., 60: 3504-3513, 2000.
58. Furnari, F. B., Lin, H., Huang, H. S., and Cavenec, W. K. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc. Natl. Acad. Sci. USA, 94: 12479-12484, 1997.
59. mapk are required for fibroblast proliferation. Proc. Natl. Acad. Sci. USA, 90: 8319-8323, 1993.
60. Cowley, S., Paterson, H., Kemp, P., and Marshall, C. J. Activation of MAP kinase kinase is necessary and sufficient for PC 12 differentiation and for transformation of NIH 3T3 cells. Cell, 77: 841-852, 1994.
61. Wu, X., Noh, S. J., Zhou, G., Dixon, J. E., and Guan, K. L. Selective activation of MEK1 but not MEK2 by A-Raf from epidermal growth factor-stimulated HeLa cells. J. Biol. Chem., 271: 3265-3271, 1996.
62. Fujio, Y., and Walsh, K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J. Biol. Chem., 274: 16349-16354, 1999.
63. Fujio, Y., Nguyen, T., Wencker, D., Kitsis, R. N., and Walsh, K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation, 101: 660-667, 2000.
64. Fulton, D., Gratton, J. P., McCabe, T. J., Fontana, J., Fujio, Y., Walsh, K., Franke, T. F., Papapetropoulos, A., and Sessa, W. C. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature (Lond.), 399: 597-601, 1999.
65. Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., and Cantley, L. C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell. 10: 151-162, 2002.
66. Capdeville, R., Buchdunger, E., Zimmermann, J., and Matter, A. Glivec (ST1571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov., 1: 493-502, 2002.
67. Cohen, P. Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug Discov., 1: 309-315, 2002.